John Sourbeer
Stock Analyst at UBS
(0.48)
# 3,830
Out of 4,818 analysts
37
Total ratings
26.32%
Success rate
-28.09%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $5.75 | +91.30% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $21.53 | +9.15% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $28.13 | +59.97% | 3 | Feb 13, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $50 → $48 | $42.13 | +13.93% | 4 | Feb 7, 2025 | |
| WST West Pharmaceutical Services | Upgrades: Buy | $350 → $390 | $210.93 | +84.90% | 3 | Dec 12, 2024 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.11 | +81.00% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $76.83 | +88.73% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $296.34 | +61.98% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $1.25 | +500.00% | 2 | Mar 5, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $38.64 | +163.98% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $8.12 | +515.76% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $270 | $144.14 | +87.32% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $128.60 | -0.47% | 2 | Jul 27, 2022 |
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $5.75
Upside: +91.30%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $21.53
Upside: +9.15%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $28.13
Upside: +59.97%
Qiagen
Feb 7, 2025
Maintains: Neutral
Price Target: $50 → $48
Current: $42.13
Upside: +13.93%
West Pharmaceutical Services
Dec 12, 2024
Upgrades: Buy
Price Target: $350 → $390
Current: $210.93
Upside: +84.90%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.11
Upside: +81.00%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $76.83
Upside: +88.73%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $296.34
Upside: +61.98%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $1.25
Upside: +500.00%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $38.64
Upside: +163.98%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $8.12
Upside: +515.76%
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $144.14
Upside: +87.32%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $128.60
Upside: -0.47%